Definium Therapeutics, Inc. (DFTX) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$131.56M | -66.3% |
| 2024 | -$79.13M | -22.9% |
| 2023 | -$64.36M | -28.4% |
| 2022 | -$50.14M | -9.4% |
| 2021 | -$45.82M | -94.2% |
| 2020 | -$23.60M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$131.56M | -66.3% |
| 2024 | -$79.13M | -22.9% |
| 2023 | -$64.36M | -28.4% |
| 2022 | -$50.14M | -9.4% |
| 2021 | -$45.82M | -94.2% |
| 2020 | -$23.60M | — |